HIGHLIGHTS
5773  Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations
5775  Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need
Malika Nusrat
See related article, p. 5887

5778  Protein Glycosylation: “New-yet-Old” Target for Immunotherapy
Jaydeep Bhat and Dieter Kabelitz
See related article, p. 5990

Reviews
5781  Radiation-induced Adaptive Response: New Potential for Cancer Treatment
C. Norman Coleman, Iris Eke, Adeola Y. Makinde, Sunita Chopra, Sandra Demaria, Silvia C. Formenti, Shannon Martello, Michelle Bylicky, James B. Mitchell, and Molykutty J. Aryankalayil

5791  Statins as Anticancer Agents in the Era of Precision Medicine
Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, and Linda Z. Penn

5801  Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
Javier Martin-Broto, David S. Moura, and Brian A. Van Tine

PERSPECTIVES

5809  The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts
Alex Broom, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, and Mustafa Khasraw

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT
5814  Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120
Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits Van Rhee, Bart Barlogie, and Robert Orlowski

CLINICAL TRIALS: TARGETED THERAPY
5820  Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romani, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaño, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, and Aleix Prat

5830  Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
# TABLE OF CONTENTS

5843  
**PI3KCA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype**  

5852  
**Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression**  

5860  
**Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck**  

## CLINICAL TRIALS: IMMUNOTHERAPY

5869  
**Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma**  

5879  
**Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation**  

5887  
**Multicenter Phase I/II Trial of Nabupucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1505/SOOP Trial)**  
Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, Hiroki Haru, Tomohiro Nishina, Yoshito Komatsu, Satoshi Yuki, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Masahito Kawazu, Hiroyuki Mano, Yosuke Togashi, Hiroyoshi Nishikawa, and Takayuki Yoshino

See related commentary, p. 5775

5895  
**Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma**  
William E. Pierceall, Michael D. Amatangelo, Nizar J. Bahlis, David S. Siegel, Adeeb Rahman, Olivier Van Oekelen, Paola Neri, Mary Young, Weiyuan Chung, Natalya Serbina, Samir Parekh, Amit Agarwal, and Anjan Thakurta

## PRECISION MEDICINE AND IMAGING

5903  
**Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation**  
Konrad H. Stoppack, Ying Huang, Svitalana Tyekucheva, Travis A. Gerke, Clyde Bango, Habiba Elandy, Michaela Bowden, Kathryn L. Penney, Thomas M. Roberts, Giovanni Parmigiani, Philip W. Kantooff, Lorelei A. Mucci, and Massimo Loda

5914  
**TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions**  
Allison S. Cohen, Jun Li, Matthew R. Hight, Elliott McKinley, Allie Fu, Adria Payne, Yang Liu, Dawei Zhang, Qing Xie, Mingfeng Bai, Gregory D. Ayers, Mohammed Noor Tantawy, Jarrod A. Smith, Frank Revetta, M. Kay Washington, Chjanju Shi, Nipun Merchant, and H. Charles Manning

5926  
**Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy**  

5934  
**Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using 111In-Labeled SGM-101**  

See related commentary, p. 5775

---

Downloaded from clinicancces.aacrjournals.org on September 18, 2021. © 2020 American Association for Cancer Research.
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5952</td>
<td>Research</td>
<td>Gene Networks Constructed Through Simulated Treatment Learning Can Predict Proteasome Inhibitor Benefit in Multiple Myeloma</td>
<td>Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, and Jeroen de Ridder</td>
</tr>
<tr>
<td>5962</td>
<td>TRANSLATIONAL CANCER MECHANISMS AND THERAPY</td>
<td>Epithelial-to-Mesenchymal Transition Is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non–Small Cell Lung Cancer</td>
<td>Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zee Tan, Rui Yamaguchi, and Hiromichi Ebi</td>
</tr>
<tr>
<td>5990</td>
<td>Research</td>
<td>Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors</td>
<td>Sailing Shi, Shengqiong Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng Jiang, Kai W. Wucherpfennig, and X. Shirley Liu</td>
</tr>
<tr>
<td>6003</td>
<td>Research</td>
<td>PD1 Blockade Enhances ICAMI-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer</td>
<td>Katherine D. Gray, Jaclyn E. McCloskey, Yogindra Vedvyas, Olivia R. Kalloo, Steve El Eshaky, Yanping Yang, Enda Shevlin, Marjan Zaman, Timothy M. Ullmann, Heng Liang, Dessislava Stefanova, Paul J. Christos, Theresa Scognamiglio, Andrew B. Tassler, Rasa Zarzegar, Thomas J. Fahey III, Moonsoo M. Jin, and Irene M. Min</td>
</tr>
</tbody>
</table>

**TABLE OF CONTENTS**


- Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma by Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, and Jeroen de Ridder

- Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non–Small Cell Lung Cancer by Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zee Tan, Rui Yamaguchi, and Hiromichi Ebi


- Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors by Sailing Shi, Shengqiong Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng Jiang, Kai W. Wucherpfennig, and X. Shirley Liu

- PD1 Blockade Enhances ICAMI-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer by Katherine D. Gray, Jaclyn E. McCloskey, Yogindra Vedvyas, Olivia R. Kalloo, Steve El Eshaky, Yanping Yang, Enda Shevlin, Marjan Zaman, Timothy M. Ullmann, Heng Liang, Dessislava Stefanova, Paul J. Christos, Theresa Scognamiglio, Andrew B. Tassler, Rasa Zarzegar, Thomas J. Fahey III, Moonsoo M. Jin, and Irene M. Min

For more information please visit www.aacrjournals.org
ABOUT THE COVER

Multiplex immunofluorescence for PI3K pathway activation on a single cell-level, using formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue on tissue microarrays (TMA). The merged image shows the following markers: PTEN (orange), stathmin (aqua), phosphoS6 (green), p63 (red), AMACR (yellow), and DAPI counterstain (blue) in a TMA core with both normal tissue (center) and invasive tumor tissue. For details, see the article by Stopsack and colleagues on page 5903 of this issue.